Log in to search using one of your social media accounts:

 

Chronic Pulmonary Aspergillosis IV
Monday, October 16, 2017 - 08:36Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 16, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Chronic Pulmonary Aspergillosis III
Monday, October 16, 2017 - 08:35Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 16, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Chronic Pulmonary Aspergillosis II
Monday, October 16, 2017 - 08:34Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 16, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Chronic Pulmonary Aspergillosis I
Monday, October 16, 2017 - 08:32Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 16, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Goldilocks and the three azoles
Friday, October 13, 2017 - 15:56Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 13, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Resistance epidemiology
Friday, October 13, 2017 - 15:54Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 13, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

News from the lab
Friday, October 13, 2017 - 15:51Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 13, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

New categories of hematological malignancies at risk for invasive fungal infections
Friday, October 13, 2017 - 15:46Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 13, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

New Preparation of Itraconazole (Pulmazole) Gets FDA Approval
Fri, 10/13/2017 - 09:59News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 13, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Voriconazole
Friday, October 13, 2017 - 09:48Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 13, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Isavuconazole
Friday, October 13, 2017 - 09:46Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 13, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

VL-2397 (Vical)
Friday, October 13, 2017 - 09:44Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 13, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

CD101 (Cidara)
Friday, October 13, 2017 - 09:42Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 13, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

APX001 (Amplyx)
Friday, October 13, 2017 - 09:41Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 13, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Galactomannan
Friday, October 13, 2017 - 09:37Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 13, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Mechanism of multidrug resistance
Friday, October 13, 2017 - 09:36Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 13, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

MALDI identification and more of mould
Friday, October 13, 2017 - 09:30Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 13, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Global burden of fungal infections
Friday, October 13, 2017 - 09:24Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 13, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

MRC Centre for Medical Mycology Scholarships
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 12, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Website terms and conditions
Before becoming a member of the Aspergillus Website you must read ourTerms and ConditionsPost date: 12 Oct 2017 - 1:39pm (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 12, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Terms and conditions of use
Terms and ConditionsWebsite terms and conditions(1)         IntroductionThese terms and conditions govern your use of our website; by using our website, you accept these terms and conditions in full. If you disagree with any part of these terms and conditions, do not use our website.(2)         Intellectual property rightsPost date: 12 Oct 2017 - 8:47am (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 12, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Interference of griseofulvin with the segregation of chromosomes at mitosis in diploid Aspergillus nidulans
Low concentrations of the antibioticgriseofulvin were found to cause increased frequencies of somatic segregation due to chromosome nondisjunction in a diploid strain ofAspergillus nidulans. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Antifungal activity of statins against Aspergillus species
The cholesterol-lowering agents known as statins have in vitro activities against human pathogenic fungi, such as Candida species, Cryptococcus neoformans, and Zygomycetes. Synergy between statins and azoles against these fungi has also been reported. We evaluated the in vitro activities of two statins, lovastatin andsimvastatin, alone and in combination with azoles and amphotericin B, against clinical isolates ofAspergillus spp. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Growth inhibition of Candida species and Aspergillus fumigatus by statins.
Statins are a class of drugs widely used for lowering high cholesterol levels through their action on 3-hydroxy-3-methylglutaryl-CoA reductase, a key enzyme in the synthesis of cholesterol. We studied the effects of two major statins,simvastatin and atorvastatin, on five Candida species andAspergillus fumigatus. The statins strongly inhibited the growth of all species, except Candida krusei. Supplementation of Candida albicans and A. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review
The efficacy and safety of amorolfine 5% nail lacquer in combination with systemic antifungal agents in the treatment of the onychomycosis were evaluated. According to our meta-analysis, combination treatment of amorolfine 5% nail lacquer and systemic antifungals can result in higher percentage of complete clearance of onychomycosis. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis
The objective of this study was to investigate patient-reported outcomes (treatment utilisation, adherence and satisfaction) in onychomycosis treated with once-weeklyamorolfine 5% nail lacquer versus once-daily ciclopirox 8% nail lacquer (Study A) or once-daily urea 40% ointment/bifonazole 1% cream combination regimen (Study B). Study A: Subjects receivedamorolfine and ciclopirox on opposite feet for 12  weeks. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Antifungal spectrum, in vivo efficacy, and structure-activity relationship of ilicicolin H
Ilicicolin H is a polyketide-nonribosomal peptide synthase (NRPS)-natural product isolated from Gliocadium roseum, which exhibits potent and broad spectrum antifungal activity, with sub- μg/mL MICs against Candida spp., Aspergillus fumigatus, and Cryptococcus spp. It showed a novel mode of action, potent inhibition (IC50 = 2-3 ng/mL) of the mitochondrial cytochrome bc1 reductase, and over 1000-fold selectivity relative to rat liver cytochrome bc1 reductase. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Efficacy of ambruticin analogs in a murine model of invasive pulmonary aspergillosis
Ambruticins are a family of polyketides. The antifungal activity of an ambruticin,KOSN-2079, was tested in the mouse model of invasive aspergillosis.KOSN-2079 significantly reduced pulmonary fungal burdens and improved survival over that with the vehicle control. These results support the continued development of ambruticins as antifungal agents. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice
The activities ofR-135853, a novel sordarin derivative that possesses a 1,4-oxazepane ring moiety, were evaluated in vitro and in vivo.R-135853 exhibited potent in vitro activities against Candida albicans (fluconazole-susceptible strains), Candida glabrata, Candida tropicalis, and Cryptococcus neoformans, with MICs at which 90% of isolates were inhibited of 0.03, 1, 0.5, and 0.5 microg/ml, respectively. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

In Vitro and In Vivo Activity of a Novel Antifungal Small Molecule against Candida Infections
Candida is the most common fungal pathogen of humans worldwide and has become a major clinical problem because of the growing number of immunocompromised patients, who are susceptible to infection. Moreover, the number of available antifungals is limited, and antifungal-resistantCandida strains are emerging. New and effective antifungals are therefore urgently needed. Here, we discovered a small molecule with activity againstCandida spp. bothin vitro andin vivo. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids
Recent estimates suggest that>300 million people are afflicted by serious fungal infections worldwide. Currentantifungal drugs are static and toxic and/or have a narrow spectrum of activity. Thus, there is an urgent need for the development of newantifungal drugs. The fungal sphingolipid glucosylceramide (GlcCer) is critical in promoting virulence of a variety of human-pathogenic fungi. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Drugs in Clinical Development for Fungal Infections (includes MAT023, encochleated amphotericin B))
Despite increasing rates of invasive fungal infections being reported globally, only a single antifungal drug has been approved during the last decade. Resistance, toxicity, drug interactions and restricted routes of administration remain unresolved issues. This review focuses on new antifungal compounds which are currently in various clinical phases of development. We discuss two azoles with a tetrazole moiety that allows selective activity against the fungal CYP: VT-1161 for Candida infections and VT-1129 for cryptococcal meningoencephalitis. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Antitumor/Antifungal Celecoxib Derivative AR-12 is a Non-Nucleoside Inhibitor of the ANL-Family Adenylating Enzyme Acetyl CoA Synthetase
AR-12/OSU-03012 is an antitumor celecoxib-derivative that has progressed to Phase I clinical trial as an anticancer agent and has activity against a number of infectious agents including fungi, bacteria and viruses. However, the mechanism of these activities has remained unclear. Based on a chemical-genetic profiling approach in yeast, we have found thatAR-12 is an ATP-competitive, time-dependent inhibitor of yeast acetyl coenzyme A synthetase. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis
Only one new class of antifungal drugs has been introduced into clinical practice in the last 30 years, and thus the identification of small molecules with novel mechanisms of action is an important goal of current anti-infective research. Here, we describe the characterization of the spectrum of in vitro activity and in vivo activity ofAR-12, a celecoxib derivative which has been tested in a phase I clinical trial as an anticancer agent. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition
The synthesis and antifungal activity ofASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition and significantly improved MIC against Candida parapsilosis and echinocandin resistant-Candida is described. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis
ASP9726 is an investigational echinocandin with in vitro activity against Aspergillus species. We evaluated the pharmacokinetics and efficacy of this agent in an established guinea pig model of invasive pulmonary aspergillosis.ASP9726 plasma concentrations were measured in guinea pigs administered either a single dose or multiple doses of this agent at 2.5, 5, and 10 mg/kg of body weight/day by subcutaneous injection. Immunosuppressed guinea pigs were inoculated with A. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Generation of Broad-Spectrum Antifungal Drug Candidates from the Natural Product Compound Aureobasidin A
This report describes novel chemistry for the modification of AbA. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

An aureobasidin A resistance gene isolated from Aspergillus is a homolog of yeast AUR1, a gene responsible for inositol phosphorylceramide (IPC) synthase activity.
We report the molecular cloning and characterization of the Aspergillus nidulans aurA gene, which is homologous to AUR1. A single point mutation in the aurA gene of A. nidulans confers a high level of resistance toaureobasidin A. The A. nidulans aurA gene was used to identify its homologs in other Aspergillus species, including A. fumigatus, A. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Structure of aureobasidin A
Aureobasidin A, a new antifungal antibiotic, was isolated from the culture medium of Aureobasidium pullulans R106.Aureobasidin A was a cyclic depsipeptide consisting of eight alpha-amino acid units and one hydroxy acid unit. The structures of the units were found by acid hydrolysis of the antibiotic to be 2(R)-hydroxy-3(R)-methylpentanoic acid, beta-hydroxy-N-methyl-L-valine, N-methyl-L-valine, L-proline, allo-L-isoleucine, N-methyl-L-phenylalanine, L-leucine, and L-phenyl-alanine. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

FR290581, a novel sordarin derivative: synthesis and antifungal activity
Sordarin is a unique natural product antifungal agent that is an inhibitor of elongation factor 2. To improve biological activity, we synthesized various compounds by novel modification of the aglycone, sordaricin. As a result, we have discovered the novel sordarin derivativeFR290581. This compound exhibited superior activity and a good pharmacokinetic profile, and also displayed good in vivo activity against Candida albicans. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Correlation between In Vitro and In Vivo Activities of GM 237354, a New Sordarin Derivative, against Candida albicans in an In Vitro Pharmacokinetic-Pharmacodynamic Model and Influence of Protein Binding
The antifungal effect ofGM 237354, a sordarin derivative, was studied in an in vitro pharmacokinetic (PK)-pharmacodynamic dynamic system (bioreactor) which reproduces PK profiles observed in a previously described model of drug efficacy against murine systemic candidiasis. Immunocompetent mice infected intravenously with 10(5) CFU of Candida albicans were treated withGM 237354 at 2.5, 10, and 40 mg/kg of body weight every 8 h subcutaneously for 7 days. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Vical announces Phase 2 efficacy trial for antifungal VL-2397
Fri, 10/06/2017 - 16:50News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Fungal Cell Walls Disrupted by Two Naturally Occurring Compounds
Fri, 10/06/2017 - 11:25News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Improving Fungal Disease Management Worldwide
Thu, 10/05/2017 - 14:35News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 5, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Drugs in Clinical Development for Fungal Infections (review includes CD101)
Despite increasing rates of invasive fungal infections being reported globally, only a single antifungal drug has been approved during the last decade. Resistance, toxicity, drug interactions and restricted routes of administration remain unresolved issues. This review focuses on new antifungal compounds which are currently in various clinical phases of development. We discuss two azoles with a tetrazole moiety that allows selective activity against the fungal CYP: VT-1161 for Candida infections and VT-1129 for cryptococcal meningoencephalitis. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 5, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Novamycin: ECCMID poster
New antifungal: click on link below (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 5, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Novamycin: short talk from Dr Deborah O'Neill at Boulder Peptide Society
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 5, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Novamycin (NP339)
Novamycin ® (NP339) is a novel antifungal peptide developed forfront-line treatment of medically unmet, yeast and mould infections, particularly those caused by Aspergillus spp. and Candida spp. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 5, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Immune Cells Trigger Spore Suicide, Stopping Fungal Infection
Tue, 10/03/2017 - 13:20News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 3, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news